Core Insights - Chemours reported $1.5 billion in revenue for Q3 2025, a year-over-year decline of 0.4% and an EPS of $0.20, down from $0.40 a year ago, indicating a significant drop in profitability [1] - The revenue exceeded the Zacks Consensus Estimate of $1.49 billion by 0.19%, while the EPS fell short of the consensus estimate of $0.24 by 16.67% [1] Revenue Performance - Other Segment revenues were $12 million, below the average estimate of $14.67 million, reflecting a year-over-year decline of 14.3% [4] - Titanium Technologies generated $612 million, compared to the average estimate of $634.1 million, marking a year-over-year decrease of 9.9% [4] - Advanced Performance Materials reported revenues of $311 million, exceeding the average estimate of $297 million, but still down 10.6% year-over-year [4] - Thermal & Specialized Solutions achieved $560 million in revenues, slightly below the average estimate of $563.96 million, but showing a year-over-year increase of 21.7% [4] Adjusted EBITDA Analysis - Adjusted EBITDA for Titanium Technologies was $25 million, significantly lower than the average estimate of $39.7 million [4] - Corporate and Other segment reported an adjusted EBITDA of -$38 million, better than the average estimate of -$50.99 million [4] - Other Segment adjusted EBITDA was $2 million, slightly below the average estimate of $2.31 million [4] - Advanced Performance Materials had an adjusted EBITDA of $14 million, close to the average estimate of $14.9 million [4] - Thermal & Specialized Solutions reported an adjusted EBITDA of $194 million, exceeding the average estimate of $179.85 million [4] Stock Performance - Chemours shares have declined by 19.9% over the past month, contrasting with a 1.3% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), suggesting potential underperformance relative to the broader market in the near term [3]

Core Insights - Chemours reported quarterly earnings of $0.20 per share, missing the Zacks Consensus Estimate of $0.24 per share, and down from $0.40 per share a year ago, representing an earnings surprise of -16.67% [1] - The company posted revenues of $1.5 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.19%, with year-ago revenues also at $1.5 billion [2] - Chemours shares have declined approximately 28.7% year-to-date, contrasting with the S&P 500's gain of 15.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.21 on revenues of $1.4 billion, and for the current fiscal year, it is $1.15 on revenues of $5.87 billion [7] - The estimate revisions trend for Chemours was unfavorable prior to the earnings release, resulting in a Zacks Rank 5 (Strong Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Chemical - Diversified industry, to which Chemours belongs, is currently ranked in the bottom 9% of over 250 Zacks industries, suggesting a challenging environment for the stock [8]

Financial Performance - Net sales decreased by $13 million (or 1%) to $1.5 billion for the three months ended September 30, 2025, compared to $1.5 billion for the same period in 2024, primarily due to a 3% decrease in volume [402]. - For the nine months ended September 30, 2025, net sales increased by $55 million (or 1%) to $4.5 billion, driven by a 2% increase in volume [404]. - The company reported a net income of $60 million for the three months ended September 30, 2025, compared to a net loss of $32 million for the same period in 2024 [400]. - Basic earnings per share for the three months ended September 30, 2025, was $0.40, compared to a loss of $0.22 for the same period in 2024 [401]. - The company reported a net loss of $387 million for the nine months ended September 30, 2025 [493]. Costs and Expenses - Cost of goods sold (COGS) increased by $40 million (or 3%) to $1.3 billion for the three months ended September 30, 2025, and by $186 million (or 5%) to $3.7 billion for the nine months ended September 30, 2025, primarily due to higher raw materials costs [407]. - Selling, general, and administrative (SG&A) expenses decreased by $28 million (or 20%) to $109 million for the three months ended September 30, 2025, but increased by $241 million (or 56%) to $669 million for the nine months ended September 30, 2025, mainly due to litigation-related charges [408]. - Research and development (R&D) expenses were $26 million and $81 million for the three and nine months ended September 30, 2025, respectively, compared to $29 million and $83 million for the same periods in 2024 [409]. - Restructuring, asset-related, and other charges decreased by $41 million (or 91%) to $4 million for the three months ended September 30, 2025, and increased by $3 million (or 6%) to $55 million for the nine months ended September 30, 2025 [410]. Segment Performance - Thermal & Specialized Solutions segment net sales increased by $92 million (or 20%) to $560 million for the three months ended September 30, 2025, and by $181 million (or 13%) to $1.6 billion for the nine months ended September 30, 2025 [428][429]. - Titanium Technologies segment net sales decreased by $60 million (or 9%) to $612 million for the three months ended September 30, 2025, and by $73 million (or 4%) to $1.9 billion for the nine months ended September 30, 2025 [435][436]. - Adjusted EBITDA for the Thermal & Specialized Solutions segment increased by $55 million (or 40%) to $194 million for the three months ended September 30, 2025, and by $93 million (or 21%) to $542 million for the nine months ended September 30, 2025 [430]. - For the three months ended September 30, 2025, Segment Adjusted EBITDA decreased by $53 million (or 68%) to $25 million, with an Adjusted EBITDA margin of 4%, down from 12% in the same period of 2024 [437]. - The Advanced Performance Materials segment's net sales decreased by $43 million (or 12%) to $311 million for the three months ended September 30, 2025, primarily due to a 15% decrease in volume, partially offset by a 2% increase in price [442]. - For the nine months ended September 30, 2025, Segment Adjusted EBITDA decreased by $109 million (or 47%) to $122 million, with an Adjusted EBITDA margin of 7%, down from 12% in the same period of 2024 [437]. - The Advanced Performance Materials segment's net sales decreased by $50 million (or 5%) to $951 million for the nine months ended September 30, 2025, primarily due to an 8% decrease in volume, partially offset by a 3% increase in price [443]. Cash Flow and Liquidity - The company generated $127 million in cash flows from operating activities for the nine months ended September 30, 2025, compared to a cash outflow of $771 million for the same period in 2024, primarily due to the release of $592 million of restricted cash [472]. - At September 30, 2025, total unrestricted cash and cash equivalents were $613 million, with $426 million held by foreign subsidiaries [459]. - The availability under the Revolving Credit Facility as of September 30, 2025, was $953 million, net of $47 million in outstanding letters of credit [459]. - The company expects liquidity from its sources to support cash needs through at least the end of November 2026 [458]. - Cash and cash equivalents decreased to $613 million at September 30, 2025, down from $713 million at December 31, 2024 [478]. Environmental and Legal Matters - The company has $609 million in environmental remediation liabilities as of September 30, 2025, with $107 million classified as current liabilities [467]. - The company expects to make significant cash payments for known obligations, including $263 million related to a settlement agreement with New Jersey over a 25-year period [469]. - The company is engaged in ongoing discussions with the U.S. EPA and NJ DEP regarding remaining remedial work at the Chambers Works site, which could materially impact financial results [517]. - The company has total environmental and legal remediation-related reserves of $147 million as of September 30, 2025, with gross liabilities estimated at approximately $248 million [544]. - The company aims for a 60% absolute reduction in Scope 1 and Scope 2 greenhouse gas emissions by 2030 [549]. Debt and Financing - The company amended its credit agreement, extending the maturity date of its $1,050 million senior secured U.S. Dollar Term Loan from August 18, 2028, to October 15, 2032 [394]. - The company declared a quarterly cash dividend of $0.0875 per share for Q3 2025, continuing its practice of returning capital to shareholders [469]. - The company anticipates remaining in compliance with applicable covenants under the Credit Agreement through at least November 2026 [462]. - The company expects to fund U.S. operations through a mix of repatriations, intercompany loans, and cash generated from operations [465]. Foreign Currency and Hedging - The Chemours Company is exposed to foreign currency exchange rate changes due to global operations, with assets, liabilities, and cash flows in various currencies [565]. - As of September 30, 2025, the company had 9 foreign currency forward contracts with a gross notional U.S. dollar equivalent of $154 million, resulting in net losses of $2 million for the three months ended [568]. - The company recognized a pre-tax loss of $53 million on its net investment hedge for the nine months ended September 30, 2025 [570]. - Interest rate swaps were utilized to mitigate cash payment volatility, with two swaps outstanding totaling $300 million as of September 30, 2025, resulting in a fair value of negative $4 million [573]. Regulatory and Compliance - The estimated earliest entry into force of PFAS restrictions is 2027, pending completion of the EU REACH restriction process [562]. - The restriction dossier for PFAS was submitted to ECHA in January 2023, with a full ban proposed and specific derogation periods considered [562]. - The company has entered into a voluntary Administrative Order on Consent with the EPA for comprehensive environmental assessment and monitoring [537]. - The company is actively working to reduce PFAS discharges and has submitted revised NPDES permit applications to address exceedances [540].

Financial Performance - Total Net Sales for Q3 2025 were $1.495 billion, flat compared to Q3 2024, with a 3% decrease in volume and a 1% increase in price [4]. - Net Income attributable to Chemours was $60 million, or $0.40 per diluted share, compared to a Net Loss of $32 million, or $(0.22) per diluted share in Q3 2024, representing a 288% year-over-year improvement [8]. - Adjusted EBITDA for Q3 2025 was $195 million, a decrease of 3% from $202 million in Q3 2024, primarily due to increased costs from operational disruptions [9]. - Free Cash Flow for Q3 2025 was $105 million, reflecting a Free Cash Flow Conversion of 54% [24]. - The company anticipates a sequential Net Sales decrease of 10-15% in Q4 2025, with Adjusted EBITDA expected to range between $130 million and $160 million [25]. - Gross profit for Q3 2025 was $233 million, down 18.5% from $286 million in Q3 2024 [37]. - Adjusted net income for the three months ended September 30, 2025, was $30 million, down from $61 million in the same period of 2024 [48]. - For the three months ended September 30, 2025, Chemours reported a net income of $60 million, compared to a net loss of $32 million in the same period of 2024 [51]. - Adjusted Net Income for the nine months ended September 30, 2025, was $165 million, down from $137 million in the same period of 2024 [51]. - Adjusted EBITDA for the nine months ended September 30, 2025, was $614 million, compared to $600 million in the same period of 2024 [54]. - The estimated Adjusted EBITDA for the year ending December 31, 2025, is projected to be between $745 million and $770 million [55]. - Chemours expects a net loss attributable to the company in the range of $318 million to $335 million for the year ending December 31, 2025 [55]. Segment Performance - The Thermal & Specialized Solutions segment reported Net Sales of $560 million, a 20% increase year-over-year, driven by an 80% increase in Opteon™ Refrigerants [10]. - Titanium Technologies segment Net Sales decreased by 9% to $612 million, primarily due to an 8% decrease in price globally [13]. - Advanced Performance Materials segment Net Sales were $311 million, a 12% decrease year-over-year, driven by a 15% decrease in volume [17]. - The Titanium Technologies segment reported net sales of $612 million for the three months ended September 30, 2025, a decrease of 9% compared to the same period in 2024 [45]. - The Advanced Performance Materials segment experienced a 12% decline in net sales, totaling $311 million for the three months ended September 30, 2025 [45]. Cash Flow and Assets - Cash provided by operating activities for the nine months ended September 30, 2025, was $127 million, a significant recovery from cash used of $771 million in the same period of 2024 [41]. - Total current assets increased to $3,207 million as of September 30, 2025, up from $3,017 million at the end of 2024 [39]. - Total liabilities rose to $7,270 million as of September 30, 2025, compared to $6,925 million at the end of 2024 [39]. - Free Cash Flows for the three months ended September 30, 2025, were $105 million, an increase from $63 million in the same period of 2024 [54]. - The Free Cash Flow Conversion rate for the three months ended September 30, 2025, was 54%, compared to 31% in the previous quarter [54]. Corporate Strategy and Agreements - A strategic agreement was announced with SRF Limited in India to support market needs for essential applications [8]. - The company anticipates guidance for Q2 2025 and full year 2025 performance, reflecting a refreshed corporate strategy [34]. Impairments and Charges - The company reported a goodwill impairment charge of $56 million in Q3 2024, which was not repeated in Q3 2025 [37]. - Litigation-related charges for the twelve months ended September 30, 2025, included $263 million related to a settlement agreement with the State of New Jersey [1]. - Environmental charges for the twelve months ended September 30, 2025, primarily included changes to remediation reserves at sites covered by the New Jersey settlement agreement [1]. Debt and Leverage - The net leverage ratio calculated using non-GAAP earnings was 4.6x for the three months ended September 30, 2025 [48]. - The total debt principal, net of cash and cash equivalents, was $3,572 million as of September 30, 2025 [48]. - The net leverage ratio calculated using GAAP measures is defined as total debt principal, net, divided by income before income taxes [1].

Core Viewpoint - Chemours has announced a fourth quarter dividend, indicating a commitment to returning value to shareholders and reflecting the company's financial health [1] Company Summary - The dividend announcement is part of Chemours' ongoing strategy to enhance shareholder returns [1] - The specific amount of the dividend has not been disclosed in the provided content [1] Industry Summary - The announcement of dividends is a common practice in the chemical industry, often signaling strong performance and stability within the sector [1]

Core Insights - The article focuses on Chemours Company (NYSE: CC) and provides insights ahead of its quarterly reports [1] Group 1 - The author has a long position in Chemours shares, indicating a positive outlook on the company's performance [1] - The article continues a tradition of reporting on Chemours before its quarterly earnings announcements, suggesting a consistent interest in the company's financial health [1]

Core Points - Chemours has announced the dates for its third quarter 2025 earnings release and webcast conference call [1] Company Information - The earnings release and conference call are part of Chemours' regular financial reporting schedule [1]

Core Insights - The U.S. industrial sector is facing challenges due to changing consumer and business spending, inflation expectations, and new trade tariffs, but opportunities exist for investors with the right positioning [2] Group 1: Chemours Co. (CC) - Chemours is not typically viewed as a consumer play, but its chemicals are essential in automotive and housing paints, which could benefit from recent Federal Reserve interest rate cuts [3][4] - The stock is currently priced at $16.11 with a 52-week range of $9.13 to $22.38 and a dividend yield of 2.17% [3] - Analysts have set a price target of $21 per share, indicating a potential upside of 36% from the current price [5] Group 2: Dow Inc. (DOW) - Dow's stock is currently at $23.84, with a 52-week range of $20.40 to $55.63 and a dividend yield of 5.87% [8] - Lower interest rates are expected to stimulate new business activity, leading to increased demand for restocking inventories, particularly in packaging materials [8][9] - The current consensus price target for Dow is $30 per share, suggesting a potential upside of 30.2% from its current trading price [10] Group 3: Nucor Corp. (NUE) - Nucor, the largest U.S. steelmaker, is well-positioned to benefit from rebounds in both residential and industrial construction due to infrastructure spending [12] - The stock is currently priced at $137.98, with a 52-week range of $97.59 to $170.52 and a dividend yield of 1.59% [11] - Nucor reported an EPS of $2.60 for the recent quarter, exceeding the consensus estimate, and is expected to see cost reductions while prices rise due to increased demand [14]

Group 1 - The Chemours Company (NYSE:CC) is considered one of the best specialty chemicals stocks to invest in, with Mizuho maintaining an Outperform rating and raising its price target from $16 to $19 due to higher market multiples [1] - Mizuho highlighted growing concerns over shared PFAS liabilities amid the impending DuPont split and other corporate changes, but noted that Chemours is not trading as if there is a significant PFAS tail risk, suggesting limited lingering liability unless bankruptcy occurs [2] - The Chemours Company manufactures a range of industrial and specialty products across various industries, including coatings, plastics, semiconductors, transportation, oil and gas, and refrigeration and air conditioning [3]

Group 1 - The Chemours Company (NYSE:CC) is considered chronically undervalued, despite concerns regarding "forever chemicals" which are believed to be behind the company [1] - Chemours delivers specialty chemicals across various industries, including refrigerants, pigments, resins, coatings, and advanced materials for applications in electronics, packaging, energy, transportation, and medical fields [1] - Mizuho analyst John Roberts raised Chemours' price target to $19 from $16 while maintaining an Outperform rating, citing favorable settlement progress regarding per- and polyfluoroalkyl substances and stronger market valuations [1]